Found 412 hits.
| 420. | Weller, K.+, Giménez-Arnau, A., Grattan, C., Asero, R., Mathelier-Fusade, P., Bizjak, M., Hanna, M., and Maurer, M.: The chronic urticaria registry: rationale, methods, and initial implementation. J. Eur. Acad. Dermatol. Venereol. 2021: 35; 721-729. IF: 9.23 |
o.420
| 81. | Maurer, M., Magerl, M., Metz, M., and Zuberbier, T.: Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J. Dtsch. Dermatol. Ges. 2013: 11; 971-978. IF: 1.81 |
| 303 | Hollis, K.+, Proctor, C., McBride, D., Balp, M. M., McLeod, L., Hunter, S., Tian, H., Khalil, S., and Maurer, M.: Comparison of urticaria activity score over 7 days (UAS7) values obtained from once-daily and twice-daily versions: results from the ASSURE-CSU study. Am. J. Clin. Dermatol. 2018: 19; 267-274. IF: 3.84 |
| 305 | Kikuchi, A., Inami, A., Nasir, F. B. M., Mohsen, A., Watanuki, S., Miyake, M., Matsuda, R., Koike, D., Ito, T., Sasakawa, J., Takeda, K., Hiraoka, K., Maurer, M. Yanai, K., Watabe, H., and Tashiro, M.+: Effects of levocetirizine and diphenhydramine on regional glucose metabolic changes and hemodynamic responses in the human prefrontal cortex during cognitive tasks. Hum. Psychopharmacol. Clin. Exp. 2018: 33; e2655. IF: 2.26 |
| 240 | Siebenhaar, F.+, von Tschirnhaus, E., Hartmann, K., Rabenhorst, A., Staubach, P., Peveling-Oberhag, A., Wagner, N., Martus, P., Carter, M. C., Metcalfe, D. D., Church, M. K., Maurer, M. and Weller, K.: Development and Validation of the Mastocytosis Quality of Life questionnaire: MC-QoL. Allergy 2016: 71; 869-877. IF: 7.36 |
| 108 | Franzke, N.+, Schäfer, I., Jost, K., Blome, C., Rustenbach, S. J., Reich, K., Reusch, M., Maurer, M. and Augustin, M.: A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 2011: 66; 665-670. IF: 6.27 |
| 110. | Giménez-Arnau, A. M., Toubi, E., Marsland, A. M., and Maurer, M.: Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2016: 30, Suppl. 5; 25-32. IF: 3.52 |
r.110
|
166. |
Maurer, M.+ and Magerl, M.: Differences and similarities in the mechanisms and clinical expression of bradykinin-mediated vs. mast cell-mediated angioedema. Clin. Rev. Allerg. Immunol. 2021: 9; 1067-1078. IF: 10.82 |
r.166
| 347 | Cherrez-Ojeda, I.+, Maurer, M., Bernstein, J. A., Vanegas, E., Felix, M., Ramon, G. D., Ensina, L. F., Larco Sousa, J. I., Matos Benavides, E. E., Cardona Villa, R., Latour Staffeld, P., Morfin-Maciel, B. M., Mori, J., Wilches, P. C.; Mata, V. L., and Cherrez, A.: Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organ. J. 2019: 12; 100011. IF: TBD (IF 2018: 3.68) |
o.347
| 387. | Weller, K.+, Donoso, T., Magerl, M., Aygören-Pürsün, E., Staubach, P., Martinez-Saguer, I., Hawro, T., Altrichter, S., Krause, K., Siebenhaar, F., Metz, M., Zuberbier, T., Freier, D., and Maurer, M.: Development of the angioedema control test (AECT) – a patient reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy 2020: 75; 1165-1177. IF: 13.15 |
o.387